We herein show Pin1-regulated gene expressions to differ between these cell lines, though Juglone still exerts an anti-oncogenic effect on both, which raises the possibility of Pin1 as a therapeutic target in prostate cancers. This evidence concerns the gene PIN1 and Familial prostate cancer.